ADSL and osteomyelitis: In a clinical MRSA‐induced osteomyelitis model in mice, LL18 exerted an immunomodulatory effect in a dose‐dependent manner as compared to the use of 28 mm VH, and a concentration of 300 μm combined with 483 μm VH eradicated the infection in 70% of individuals and tissue damage (Figure 11C).[133] Osteomyelitis treatment has encouraged further research into the ability of AMPs to clear infection while stimulating bone regeneration.